- Market Size (2026)
- USD 14.8 Bn
- Forecast (2036)
- USD 36.6 Bn
- CAGR (2026 to 2036)
- 9.5%
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Size, Market Forecast and Outlook By FMI
The castration-resistant prostate cancer (crpc) treatment market was valued at USD 13.5 billion in 2025. The market is set to reach USD 14.8 billion by 2026-end and grow at a CAGR of 9.5% between 2026-2036 to reach USD 36.6 billion by 2036. Hormonal Therapy will dominate with a 42.6% share, while Non-Steroidal Antiandrogens will lead with a 39.8% share.
Summary of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market
- Demand and Growth Drivers
- Expanding use of next generation androgen receptor signaling inhibitors, including enzalutamide and abiraterone, as standard first line CRPC therapy is sustaining revenue growth from high cost branded oncology pharmaceuticals.
- Pipeline advancement in PARP inhibitors, radioligand therapies, and bispecific antibodies for CRPC is expected to create new treatment lines and expand the per patient pharmaceutical spend over the disease course.
- Improved diagnostic detection of castration resistance through PSA monitoring and imaging advances is identifying CRPC patients earlier, expanding the treatment eligible population and duration of pharmacotherapy.
- Product and Segment View
- Hormonal Therapy holds 42.6% of the Therapy Type segment in 2026, reflecting the established use of androgen receptor signaling inhibitors as the backbone of CRPC treatment across both metastatic and non metastatic disease settings.
- Hospital Pharmacies account for 66.8% of the Distribution Channel segment, reflecting the specialist oncology setting where CRPC diagnosis, treatment initiation, and monitoring are primarily conducted.
- Metastatic CRPC at 64.7% of the Disease Stage segment reflects the primary disease staging where pharmacotherapy is most intensively utilized.
- Geography and Competitive Outlook
- China leads growth at 10.3% CAGR through 2036, reflecting expanding urological oncology infrastructure, growing adoption of next generation hormonal therapies, and increasing prostate cancer screening that identifies CRPC earlier in the disease course.
- The USA at 10.1% reflects the highest per patient treatment expenditure, earliest adoption of newly approved therapies, and the most comprehensive biomarker driven treatment selection protocols.
- Pharmaceutical companies with approved androgen receptor inhibitors, PARP inhibitors, and radioligand therapies, combined with global specialty oncology distribution capability, are positioned to capture the majority of market growth.
- Analyst Opinion
- Sabyasachi Ghosh, Principal Consultant at FMI says, 'The CRPC treatment landscape is shifting toward earlier intervention with potent androgen receptor signaling inhibitors and combination regimens that integrate targeted therapies with established hormonal approaches. Companies with late stage pipeline assets in PARP inhibitors, radioligand therapies, and bispecific antibodies for CRPC are positioned to capture significant revenue as treatment sequencing evolves and biomarker driven patient selection expands the eligible population for targeted interventions.'
- The castration-resistant prostate cancer (crpc) treatment market is transitioning toward more structured procurement and supply chain relationships.
- Adoption is increasing due to evolving regulatory requirements and commercial performance benchmarks.
- Demand is further supported by evolving standards across North America, Europe, and East Asia.
-treatment-market-value-analysis.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Value Analysis")
Key Takeaways, Market Size, and Forecast
- The castration-resistant prostate cancer (crpc) treatment market was valued at USD 13.53 billion in 2025.
- By 2036, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to be worth USD 36.63 billion.
- From 2026 to 2036, the market is projected to expand at a CAGR of 9.5%.
- The market is projected to create an incremental opportunity of USD 21.85 billion between 2026 and 2036.
- In 2026, Hormonal Therapy is expected to account for 42.6% of the Therapy Type, driven by established use of androgen receptor signaling inhibitors and next generation hormonal agents as first line therapy in both metastatic and non metastatic CRPC treatment settings.
- China (10.3%) and USA (10.1%) are two of the fastest growing markets in the world.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Definition
The castration-resistant prostate cancer treatment market encompasses pharmaceutical products indicated for the treatment of prostate cancer that progresses despite androgen deprivation therapy. Treatment categories include next generation hormonal therapies, chemotherapy, PARP inhibitors, immunotherapy, radioligand therapy, and supportive care medications.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Inclusions
Market scope covers all commercially marketed CRPC treatment products categorized by Therapy Type, Drug Class, Disease Stage, Delivery Method, Distribution Channel, End User. Revenue sizing spans the 2026 to 2036 forecast period.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Exclusions
The scope does not include hormone sensitive prostate cancer treatments used prior to castration resistance, diagnostic imaging equipment, surgical procedures, or radiation therapy services.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Research Methodology
- Primary Research: FMI analysts conducted interviews with manufacturers, specialists, and supply chain participants across key markets.
- Desk Research: Combined industry databases, regulatory filings, trade publications, and manufacturer disclosures.
- Market Sizing and Forecasting: Bottom up aggregation across segments, applications, and regions with adoption curve modeling.
- Data Validation: Cross checked quarterly against production statistics, trade data, and reported figures.
Why is the Castration-Resistant Prostate Cancer (CRPC) Treatment Market Growing?
- Treatment paradigm evolution toward earlier and more aggressive pharmacotherapy intervention in CRPC, including intensified hormonal blockade and combination targeted therapy approaches, is expanding per patient drug utilization and revenue.
- Biomarker driven patient selection using homologous recombination deficiency testing and PSMA imaging is enabling targeted therapies to reach specific CRPC subpopulations, creating premium revenue opportunities for precision oncology products.
- China leads growth at 10.3% CAGR, reflecting rapid expansion of urological oncology treatment capacity and increasing adoption of international CRPC treatment guidelines.
The CRPC treatment market is expanding rapidly as treatment options multiply and intervention timing moves earlier in the disease course. Hormonal therapy accounts for 42.6% of the therapy type segment, reflecting the foundational role of next generation androgen receptor signaling inhibitors in CRPC management. Chemotherapy, targeted therapy, immunotherapy, and radioligand therapy serve complementary roles in treatment sequencing, with selection increasingly guided by molecular profiling and disease staging.
The commercial landscape is characterized by high per patient treatment costs and extended treatment durations. Next generation hormonal agents like enzalutamide and abiraterone generate annual per patient revenues exceeding USD 50,000 in major markets. PARP inhibitors for HRD positive CRPC and PSMA targeted radioligand therapies are adding incremental treatment lines that further increase lifetime pharmaceutical spend per patient. This expanding treatment cascade is the primary driver of market revenue growth.
Payer access and pricing pressure are intensifying as the CRPC treatment portfolio expands and per patient costs increase. Health technology assessment bodies in Europe, outcomes based contracting in the USA, and reimbursement negotiations in East Asia are creating market access complexity for newly launched therapies. Companies with comprehensive health economic evidence, patient access programs, and flexible pricing strategies across income level tiers maintain the broadest market access profiles.
Market Segmentation Analysis
- Hormonal Therapy holds 42.6% of the Therapy Type segment, supported by established demand.
- Hospital Pharmacies accounts for 66.8% of the Distribution Channel segment, reflecting core buyer concentration.
- Metastatic CRPC at 64.7% of the Disease Stage segment reflects functional and logistical preferences.
The castration-resistant prostate cancer (crpc) treatment market is segmented by Therapy Type, Drug Class, Disease Stage, Delivery Method, Distribution Channel, End User.
Insights into the Hormonal Therapy Therapy Type Segment
-treatment-market-analysis-by-therapy-type.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Analysis By Therapy Type")
In 2026, Hormonal Therapy is expected to account for 42.6% of the Therapy Type segment. This position reflects sustained demand where hormonal therapy has demonstrated consistent efficacy and cost effectiveness. Sub segments are differentiated by specifications and pricing. Procurement decisions prioritize supply reliability, regulatory compliance, and quality consistency.
Insights into the Hospital Pharmacies Distribution Channel Segment
-treatment-market-analysis-by-distribution-channel.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Analysis By Distribution Channel")
Hospital Pharmacies accounts for 66.8% of the Distribution Channel segment. Growth is supported by expanding addressable markets and standardization. Buyers prioritize performance consistency, total cost considerations, and technical support availability.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Drivers, Restraints, and Opportunities
- Regulatory frameworks create structured demand for compliant products.
- Cost constraints and supply limitations present margin compression risks.
- Application expansion creates incremental growth opportunities.
The castration-resistant prostate cancer (crpc) treatment market is shaped by regulatory mandates, shifting requirements, and competitive dynamics across product categories and geographies.
Treatment Sequencing Expansion and Per Patient Revenue Growth
Demand is shaped by the expanding number of approved treatment lines available for CRPC patients, which increases the total pharmaceutical spend over the disease course. Patients now commonly receive sequential hormonal therapy, chemotherapy, targeted therapy, and radioligand therapy, with each treatment line generating significant pharmaceutical revenue. Earlier treatment initiation and longer survival are extending the duration of pharmacotherapy.
Payer Access and Cost Containment Pressure
Growth is constrained by increasing payer scrutiny of CRPC treatment costs, particularly for newly approved therapies that add incremental treatment lines without curative intent. Health technology assessment bodies in Europe and formulary review committees in the USA evaluate cost effectiveness evidence that influences market access and reimbursement levels. Biosimilar competition for established hormonal agents is beginning to affect pricing in some markets.
Biomarker Driven Precision Oncology
Adoption is increasing due to expanding use of molecular profiling to select targeted therapies for specific CRPC subpopulations. Homologous recombination deficiency testing identifies patients eligible for PARP inhibitor therapy, while PSMA expression assessment guides radioligand therapy selection. This precision approach creates premium revenue streams for targeted agents while improving clinical outcomes.
Emerging Market Oncology Infrastructure Expansion
Growth reflects expanding urological oncology treatment capacity in China, India, and other emerging markets where increasing prostate cancer screening, specialist physician availability, and reimbursement pathways are enabling adoption of international CRPC treatment standards. These markets represent the fastest growing patient populations for CRPC pharmacotherapy.
Analysis of Castration-Resistant Prostate Cancer (CRPC) Treatment Market By Key Countries
-treatment-market-cagr-(2026-2036).webp "Top Country Growth Comparison Castration Resistant Prostate Cancer (crpc) Treatment Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 10.1% |
| India | 9.2% |
| China | 10.3% |
| UK | 9.1% |
| Germany | 9.4% |
| South Korea | 9.6% |
| Japan | 9.3% |
| France | 9.2% |
| Italy | 9.1% |
| Australia-New Zealand | 9.4% |
-treatment-market-cagr-analysis-by-country.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Cagr Analysis By Country")
- China leads with 10.3% CAGR through 2036.
- USA at 10.1% demonstrates sustained demand.
- India (9.2%) reflects steady demand from established industries.
The global castration-resistant prostate cancer (crpc) treatment market is projected to grow at 9.5% CAGR from 2026 to 2036. The analysis covers more than 30 countries.
Demand Outlook for CRPC Treatment Market in the United States
The United States is expected to grow at 10.1% CAGR through 2036. The US CRPC market reflects the highest per patient treatment expenditure driven by aggressive treatment sequencing, early adoption of PARP inhibitors and radioligand therapies, and comprehensive insurance coverage that supports multi line branded oncology drug utilization.
- Highest per patient treatment spending sustains premium oncology drug revenue.
- Earliest adoption of newly approved targeted and radioligand therapies.
- Biomarker driven treatment selection expands targeted therapy utilization.
Future Outlook for CRPC Treatment Market in India
India is expected to grow at 9.2% CAGR through 2036. Growing urological oncology specialist capacity and the availability of generic abiraterone and enzalutamide are expanding access to next generation hormonal therapy for CRPC patients, with cancer hospital network expansion enabling treatment delivery beyond the traditional metropolitan tertiary care concentration.
- Generic abiraterone and enzalutamide availability expands treatment access.
- Cancer hospital network expansion enables treatment beyond metropolitan centers.
- Growing specialist capacity supports adoption of international treatment guidelines.
Opportunity Analysis of CRPC Treatment Market in China
China is expected to grow at 10.3% CAGR through 2036. China's CRPC treatment market is expanding rapidly as NMPA drug approvals accelerate, National Reimbursement Drug List updates expand coverage for hormonal and targeted agents, and growing prostate cancer screening in urban hospitals increases the rate at which CRPC is diagnosed and treated.
- NMPA regulatory acceleration speeds market access for CRPC drugs.
- NRDL updates expand insurance coverage for hormonal and targeted agents.
- Urban hospital prostate cancer screening increases CRPC patient identification.
In-depth Analysis of CRPC Treatment Market in Germany
Germany is expected to grow at 9.4% CAGR through 2036. German urological oncology centers maintain comprehensive CRPC treatment protocols integrating hormonal therapy, chemotherapy, PARP inhibitors, and radioligand therapy, with AMNOG assessment providing structured early market access for newly approved agents at health system negotiated prices.
- Comprehensive urological oncology centers deliver multi modality CRPC treatment.
- AMNOG assessment enables structured early access for newly approved agents.
- High clinical trial participation supports early access to investigational therapies.
Sales Analysis of CRPC Treatment Market in South Korea
South Korea is expected to grow at 9.6% CAGR through 2036. South Korea's advanced oncology treatment infrastructure, including lutetium-177 PSMA radioligand therapy capability, positions the country as an early adopter of precision oncology approaches for CRPC management, with HIRA reimbursement supporting access to branded targeted therapies.
- Advanced oncology infrastructure supports radioligand therapy delivery.
- HIRA reimbursement covers branded CRPC targeted therapies.
- Precision oncology approaches expand biomarker driven treatment selection.
In-depth Analysis of CRPC Treatment Market in Japan
Japan is expected to grow at 9.3% CAGR through 2036. Japan's PMDA regulatory pathways and national health insurance coverage support comprehensive CRPC pharmacotherapy, with Japanese urological oncology guidelines incorporating next generation hormonal agents, PARP inhibitors, and radioligand therapy consistent with international treatment standards.
- PMDA pathways support timely access to CRPC treatment advances.
- National health insurance covers comprehensive CRPC pharmacotherapy.
- Japanese urological guidelines align with international treatment standards.
Competitive Landscape and Strategic Positioning
-treatment-market-analysis-by-company.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Analysis By Company")
- Johnson & Johnson maintains the strongest position through capability and portfolio breadth.
- Pfizer Inc. / Astellas Pharma, Inc., Bayer AG, Novartis AG compete through specialization and regional expertise.
- Emerging players focus on niche applications and differentiation.
Johnson & Johnson holds the strongest competitive position through technical capability, established relationships, and portfolio breadth. The company benefits from multi regional presence and regulatory infrastructure.
Pfizer Inc. / Astellas Pharma, Inc., Bayer AG, Novartis AG compete through specialized capabilities, application expertise, and targeted strategies that provide advantages in specific segments or geographies.
Barriers to entry include technical expertise, regulatory compliance costs, established relationships, and capital requirements. New participants focus on niche opportunities where incumbent coverage is limited.
Strategic priorities include cost optimization, geographic expansion, portfolio extension, and investment in capabilities that strengthen customer retention and recurring revenue.
Key Companies in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Key global companies leading the castration-resistant prostate cancer (crpc) treatment market include:
- Johnson & Johnson, Pfizer Inc. / Astellas Pharma, Inc., Bayer AG, Novartis AG maintain strong positions through integrated capabilities and established relationships.
- AstraZeneca PLC, Merck & Co., Sanofi S.A. compete through regional specialization and targeted development.
- Abbott Laboratories, GlaxoSmithKline PLC, Dendreon Corporation, Bristol-Myers Squibb, Amgen Inc., Clovis Oncology, Endo Pharmaceuticals are establishing presence through niche focus and differentiation.
Competitive Benchmarking: Castration-Resistant Prostate Cancer (CRPC) Treatment Market
| Company | Pipeline Depth | Commercial Scale | Market Access | Clinical Evidence |
|---|---|---|---|---|
| Johnson & Johnson | High | High | Strong | Global |
| Pfizer Inc. / Astellas Pharma, Inc. | High | High | Strong | Global |
| Bayer AG | High | High | Strong | Global |
| Novartis AG | Medium | High | Moderate | Global |
| AstraZeneca PLC | Medium | Medium | Moderate | Regional |
| Merck & Co. | Medium | Medium | Moderate | Regional |
| Sanofi S.A. | Low | Medium | Low | Regional |
| Abbott Laboratories | Low | Medium | Low | Niche |
| GlaxoSmithKline PLC | Low | Medium | Low | Niche |
| Dendreon Corporation | Low | Medium | Low | Niche |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Castration-Resistant Prostate Cancer (CRPC) Treatment Market
- In 2025, Johnson & Johnson strengthened its oncology and prostate cancer pipeline through expanded solid tumor research programs and strategic oncology acquisitions.
- In 2025, Pfizer Inc. / Astellas Pharma, Inc. reported positive long-term clinical results for XTANDI (enzalutamide) in metastatic prostate cancer and continued expanding commercialization activities across global markets, including China.
Key Players in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Major Global Players
- Johnson & Johnson
- Pfizer Inc. / Astellas Pharma, Inc.
- Bayer AG
- Novartis AG
- AstraZeneca PLC
- Merck & Co.
- Sanofi S.A.
Emerging Players/Startups
- Abbott Laboratories
- GlaxoSmithKline PLC
- Dendreon Corporation
- Bristol-Myers Squibb
- Amgen Inc.
- Clovis Oncology
- Endo Pharmaceuticals
Report Scope and Coverage
-treatment-market-breakdown-by-therapy-type,-drug-class,-and-region.webp "Castration Resistant Prostate Cancer (crpc) Treatment Market Breakdown By Therapy Type, Drug Class, And Region")
| Parameter | Details |
|---|---|
| Quantitative Units | USD 14.78 billion to USD 36.63 billion, at a CAGR of 9.5% |
| Market Definition | The castration-resistant prostate cancer (crpc) treatment market encompasses commercially traded products categorized by Therapy Type, Drug Class, Disease Stage, Delivery Method, Distribution Channel, End User. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, India, China, UK, Germany, South Korea, Japan, France, Italy, Australia-New Zealand, 30 plus countries |
| Key Companies Profiled | Johnson & Johnson, Pfizer Inc. / Astellas Pharma, Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Merck & Co., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline PLC, Dendreon Corporation, Bristol-Myers Squibb, Amgen Inc., Clovis Oncology, Endo Pharmaceuticals |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom up and top down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by Therapy Type:
- Hormonal Therapy
- ADT
- Next-Generation Hormonal Agents
- Chemotherapy
- Taxane-Based Chemotherapy
- Cytotoxic Drug Regimens
- Immunotherapy
- Immune Checkpoint Inhibitors
- Cancer Vaccine Therapies
- Radiotherapy
- Palliative Bone Radiotherapy
- Targeted External Beam Radiation
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by Drug Class:
- Non-Steroidal Antiandrogens
- Androgen Receptor Blockers
- AR Signaling Inhibitors
- Antineoplastic Agents
- Chemotherapeutic Cytotoxics
- Combination Oncology Drugs
- Microtubule Inhibitors
- Docetaxel Class Agents
- Cell Division Disruption Therapies
- Corticosteroids
- Symptom Management Steroids
- Palliative Support Agents
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by Disease Stage:
- Metastatic CRPC
- Bone Metastasis Cases
- Lymph Node & Visceral Spread
- Non-Metastatic CRPC
- Rising PSA Levels
- High-Risk Progression Cases
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by Delivery Method:
- Oral Route
- Oral Hormonal Agents
- Home-Based Long-Term Therapy
- Injectable Route
- Intramuscular Hormone Therapy
- IV Chemotherapy Infusions
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by Distribution Channel:
- Hospital Pharmacies
- Oncology Specialty Hospitals
- Inpatient Cancer Treatment Units
- Retail Pharmacies
- Community Oncology Pharmacies
- Post-Therapy Drug Dispensing
- Online Pharmacies
- E-Pharmacy Oncology Support Drugs
- Home Delivery Cancer Care Medications
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Segmented by End User:
- Hospitals
- Oncology Departments
- Urology Specialty Units
- Specialty Clinics
- Cancer Care Centers
- Outpatient Oncology Clinics
- Ambulatory Surgical Centers
- Day Care Chemotherapy Units
- Infusion Therapy Centers
Castration-Resistant Prostate Cancer (CRPC) Treatment Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. European Medicines Agency. (2024). EMA Oncology Drug Assessment Reports: Prostate Cancer Therapies. EMA.
- 2. USA Food and Drug Administration. (2025). FDA Oncology Center of Excellence: CRPC Drug Approvals. FDA.
- 3. National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines: Prostate Cancer. NCCN.
- 4. World Health Organization. (2025). WHO Global Cancer Observatory: Prostate Cancer Incidence Data. WHO.
- 5. National Cancer Institute. (2025). NCI SEER Cancer Statistics: Prostate Cancer Survival and Treatment. NCI.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Addresses
- Estimating market size and revenue from 2026 to 2036.
- Segmentation by product, application, end use, and region.
- Insights about more than 30 regional markets.
- Technology, manufacturing, and supply chain analysis.
- Competitive landscape assessment.
- Investment opportunity identification across key segments.
- Supply chain and distribution channel analysis.
- Data delivery in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Castration-Resistant Prostate Cancer (CRPC) Treatment Market in 2026?
In 2026, the global castration-resistant prostate cancer (crpc) treatment market is expected to be worth USD 14.78 billion.
How big will the Castration-Resistant Prostate Cancer (CRPC) Treatment Market be in 2036?
By 2036, the castration-resistant prostate cancer (crpc) treatment market is expected to reach USD 36.63 billion.
How much is demand for Castration-Resistant Prostate Cancer (CRPC) Treatment Market expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 9.5%.
Which Therapy Type is expected to lead in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market in 2026?
Hormonal Therapy is expected to account for 42.6% of the Therapy Type segment in 2026.
What is causing demand to rise in China in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?
China is expected to grow at 10.3% CAGR through 2036, supported by domestic scale and favorable conditions.
What is causing demand to rise in USA in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?
USA is expected to grow at 10.1% CAGR through 2036, driven by established procurement channels.
What does this report mean by 'Castration-Resistant Prostate Cancer (CRPC) Treatment Market definition'?
The castration-resistant prostate cancer (crpc) treatment market includes all commercially traded products categorized by Therapy Type, Drug Class, Disease Stage, Delivery Method, Distribution Channel, End User.
How does FMI make the Castration-Resistant Prostate Cancer (CRPC) Treatment Market forecast?
Forecasting models use a hybrid bottom up and top down approach, starting with verified transaction data and validating against industry statistics and manufacturer disclosures.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Therapy Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Therapy Type , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Therapy Type , 2026 to 2036
- Hormonal Therapy
- ADT
- Next-Generation Hormonal Agents
- Chemotherapy
- Taxane-Based Chemotherapy
- Cytotoxic Drug Regimens
- Immunotherapy
- Immune Checkpoint Inhibitors
- Cancer Vaccine Therapies
- Radiotherapy
- Palliative Bone Radiotherapy
- Targeted External Beam Radiation
- Hormonal Therapy
- Y-o-Y Growth Trend Analysis By Therapy Type , 2021 to 2025
- Absolute $ Opportunity Analysis By Therapy Type , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Drug Class
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Drug Class, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Drug Class, 2026 to 2036
- Non-Steroidal Antiandrogens
- Androgen Receptor Blockers
- AR Signaling Inhibitors
- Antineoplastic Agents
- Chemotherapeutic Cytotoxics
- Combination Oncology Drugs
- Microtubule Inhibitors
- Docetaxel Class Agents
- Cell Division Disruption Therapies
- Corticosteroids
- Symptom Management Steroids
- Palliative Support Agents
- Non-Steroidal Antiandrogens
- Y-o-Y Growth Trend Analysis By Drug Class, 2021 to 2025
- Absolute $ Opportunity Analysis By Drug Class, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Disease Stage
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Disease Stage, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Disease Stage, 2026 to 2036
- Metastatic CRPC
- Bone Metastasis Cases
- Lymph Node & Visceral Spread
- Non-Metastatic CRPC
- Rising PSA Levels
- High-Risk Progression Cases
- Metastatic CRPC
- Y-o-Y Growth Trend Analysis By Disease Stage, 2021 to 2025
- Absolute $ Opportunity Analysis By Disease Stage, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Delivery Method
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Delivery Method, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Delivery Method, 2026 to 2036
- Oral Route
- Oral Hormonal Agents
- Home-Based Long-Term Therapy
- Injectable Route
- Intramuscular Hormone Therapy
- IV Chemotherapy Infusions
- Oral Route
- Y-o-Y Growth Trend Analysis By Delivery Method, 2021 to 2025
- Absolute $ Opportunity Analysis By Delivery Method, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Distribution Channel
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Distribution Channel, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Distribution Channel, 2026 to 2036
- Hospital Pharmacies
- Oncology Specialty Hospitals
- Inpatient Cancer Treatment Value (USD Million)s
- Retail Pharmacies
- Community Oncology Pharmacies
- Post-Therapy Drug Dispensing
- Online Pharmacies
- E-Pharmacy Oncology Support Drugs
- Home Delivery Cancer Care Medications
- Hospital Pharmacies
- Y-o-Y Growth Trend Analysis By Distribution Channel, 2021 to 2025
- Absolute $ Opportunity Analysis By Distribution Channel, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- Hospitals
- Oncology Departments
- Urology Specialty Value (USD Million)s
- Specialty Clinics
- Cancer Care Centers
- Outpatient Oncology Clinics
- Ambulatory Surgical Centers
- Day Care Chemotherapy Value (USD Million)s
- Infusion Therapy Centers
- Hospitals
- Y-o-Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Therapy Type
- By Drug Class
- By Disease Stage
- By Delivery Method
- By Distribution Channel
- By End User
- Competition Analysis
- Competition Deep Dive
- Johnson & Johnson
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Pfizer Inc. / Astellas Pharma, Inc.
- Bayer AG
- Novartis AG
- AstraZeneca PLC
- Merck & Co.
- Sanofi S.A.
- Abbott Laboratories
- GlaxoSmithKline PLC
- Dendreon Corporation
- Bristol-Myers Squibb
- Amgen Inc.
- Clovis Oncology
- Endo Pharmaceuticals
- Johnson & Johnson
- Competition Deep Dive
- Assumptions & Acronyms Used
